Allakos ended the fourth quarter of 2024 with $80.8 million in cash, cash equivalents and investments. Allakos’ financial outlook, restructuring activities and estimated cash outlook as reported by ...

In a turbulent market environment, Allakos Inc . (NASDAQ:ALLK) stock has touched a new 52-week low, reaching a price level of just $0.3. While the stock appears undervalued according to ...

Allakos Inc. (NASDAQ:ALLK – Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 1,940,000 ...

Allakos (ALLK) ended the fourth quarter of 2024 with $80.8M in cash, cash equivalents and investments.Light Up your Portfolio with Spark:Easily ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).

Explore Allakos stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ALLK. Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok ...

SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic ...

Allakos ended the fourth quarter of 2024 with $80.8 million in cash, cash equivalents and investments. Allakos’ financial outlook, restructuring activities and estimated cash outlook as reported ...

Allakos ended the fourth quarter of 2024 with $80.8 million in cash, cash equivalents and investments. Allakos' financial outlook, restructuring activities and estimated cash outlook as reported by ...

(MENAFN- GlobeNewsWire - Nasdaq) SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the“Company”) (Nasdaq: ALLK), a biotechnology company that ...